Proprietary R&D

In-house R&D on development of novel platform technologies and drug discovery

Drug discovery

In the scope of its in-house drug discovery program, ACIES BIO uses its expertise in biosynthetic engineering and synthetic chemistry to develop of novel bioactive compounds focusing on anti-infective, anticancer, anti-inflammatory and neuroregenerative applications.
The approaches used in our drug discovery program are a combination of:

  • genetic engineering of metabolic pathways as well as biosynthetic engineering of large multi-modular enzyme complexes such as polyketide synthases and non-ribosomal peptide synthetases (NRPS), encoding for biosynthesis polyketides (PKS engineering), in combination with chemobiosynthesis to produce novel structural analogs, 
  • semi-synthetic derivatisation of compounds produces by biosynthesis and/or chemobiosynthesis or 
  • chemical synthesis of novel compounds or structural analogs of existing compounds

ACIES BIO drug discovery pipeline is mainly focused on the following areas:

  • new macrolactone-class bioactive compounds, developed using biosynthetic engineering and chemobiosynthetic approaches;
  • new tetracycline-class bioactive compounds, developed using biosynthetic engineering and semi-synthetic approaches.

ACIES BIO is currently looking for co-development / licensing partner for each of these drug discovery pipelines.


Acies was part of Bio World 2017, a unique forum for industry global leaders, policy makers and investors.  
The action is co-financed by the Republic of Slovenia and European Union from European Regional Development Fund.

More >>
Within public call "Enhancing innovation potential and competences in companies", Acies Bio was recognised as one of the innovative companies with best potential to contribute to international competitiveness of Slovenia through smart specialisation.


More >>